Drug Trial Radar · NCT05151744
A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
187
Actual
Start
Dec 17, 2021
Primary completion
Apr 17, 2024
Study completion Oct 1, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of vamikibart in combination with, anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with ranibizumab alone in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be 76 weeks.
Conditions
- Diabetic Macular Edema
Interventions
VamikibartDrug
Vamikibart will be administered by IVT injection in the study eye.
RanibizumabDrug
Ranibizumab will be administered by IVT injection in the study eye.
Sham ProcedureOther
Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48 in Treatment-naïve ParticipantsTime frame: Baseline, Week 44 and Week 48
Locations
38 sites in 9 countries. Site status is shown where the registry gives one.
Win Retina
Arcadia, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Bay Area Retina Associates
Walnut Creek, California
Florida Eye Associates
Melbourne, Florida
Retina Vitreous Associates of Florida
Tampa, Florida
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Deep Blue Retina PLLC
Southaven, Mississippi
Verum Research LLC
Eugene, Oregon
Texas Retina Associates
Arlington, Texas
Retina Consultants of Texas
Bellaire, Texas
Organizacion Medica de Investigacion
Buenos Aires, Argentina
Centro Oftalmológico Dr. Charles S.A.
Capital Federal, Argentina
Oftalmos
Capital Federal, Argentina
Buenos Aires Mácula
Ciudad Autonoma Buenos Aires, Argentina
Grupo Laser Vision
Rosario, Argentina
Retina Institute of Ottawa
Ottawa, Ontario, Canada
Toronto Retina Institute
Toronto, Ontario, Canada
Institut De L'Oeil Des Laurentides
Boisbriand, Quebec, Canada
Rambam Medical Center
Haifa, Israel
Hadassah MC
Jerusalem, Israel
Rabin MC
Petah Tikva, Israel
Kaplan Medical Center
Rehovot, Israel
Tel Aviv Sourasky MC
Tel Aviv, Israel
Niepubliczny Zak?ad Opieki Zdrowotnej PRYZMAT-OKULISTYKA
Gliwice, Poland
Centrum Medyczne UNO-MED
Krakow, Poland
Centrum Diagnostyki i Mikrochirurgii Oka LENS
Olsztyn, Poland
Caminomed
Tarnowskie Góry, Poland
Emanuelli Research and Development Center LLC
Arecibo, Puerto Rico
Pusan National University Hospital
Busan, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Kim's Eye Hospital
Seoul, South Korea
Clinica Universitaria de Navarra
Madrid, Spain
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain
Gloucestershire Hospitals NHS Foundation Trust
Gloucestershire, United Kingdom
Royal Surrey County Hospital
Guildford, United Kingdom
Kings College Hospital NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.